EA201891913A1 - Улучшенные препараты клеток-предшественников взрослой печени - Google Patents

Улучшенные препараты клеток-предшественников взрослой печени

Info

Publication number
EA201891913A1
EA201891913A1 EA201891913A EA201891913A EA201891913A1 EA 201891913 A1 EA201891913 A1 EA 201891913A1 EA 201891913 A EA201891913 A EA 201891913A EA 201891913 A EA201891913 A EA 201891913A EA 201891913 A1 EA201891913 A1 EA 201891913A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
adolescent
adult liver
preparations
improved preparations
Prior art date
Application number
EA201891913A
Other languages
English (en)
Other versions
EA039743B1 (ru
Inventor
Катрин Ломбар
Пьерр-Эдуард Долле
Этьенн Сокаль
Мустафа Наджими
Original Assignee
Университе Католик Де Лувэн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Университе Католик Де Лувэн filed Critical Университе Католик Де Лувэн
Publication of EA201891913A1 publication Critical patent/EA201891913A1/ru
Publication of EA039743B1 publication Critical patent/EA039743B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)

Abstract

Препараты клеток-предшественников взрослой печени (называемые HHALPC) получали от разных доноров-людей и характеризовали с использованием маркеров клеточной поверхности, которые позволяют идентифицировать препараты HHALPC и/или способы их получения, которые наиболее подходят для клеточной терапии, в частности для лечения заболеваний печени или наследственных нарушений свертываемости крови.
EA201891913A 2016-03-02 2017-03-02 Улучшенные препараты клеток-предшественников взрослой печени EA039743B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158327 2016-03-02
PCT/EP2017/054859 WO2017149059A1 (en) 2016-03-02 2017-03-02 Improved preparations of adult liver progenitor cells

Publications (2)

Publication Number Publication Date
EA201891913A1 true EA201891913A1 (ru) 2019-02-28
EA039743B1 EA039743B1 (ru) 2022-03-05

Family

ID=55696855

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891913A EA039743B1 (ru) 2016-03-02 2017-03-02 Улучшенные препараты клеток-предшественников взрослой печени

Country Status (14)

Country Link
US (1) US20190046584A1 (ru)
EP (1) EP3423566A1 (ru)
JP (1) JP2019506890A (ru)
KR (1) KR20180114073A (ru)
CN (1) CN108779440A (ru)
AU (1) AU2017225825A1 (ru)
BR (1) BR112018067597A8 (ru)
CA (1) CA3013427A1 (ru)
EA (1) EA039743B1 (ru)
IL (1) IL261383A (ru)
MA (1) MA45274A (ru)
MX (1) MX2018010508A (ru)
SG (1) SG11201807041PA (ru)
WO (1) WO2017149059A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
TW202035682A (zh) 2018-12-14 2020-10-01 比利時商普羅米修亞生物科技股份有限公司 表現hla-g之肝先驅細胞及取得包含該等細胞之此等細胞組成物之方法與其用途
SG11202106169SA (en) 2018-12-14 2021-07-29 Promethera Therapeutics Sa Cell composition comprising liver progenitor cells expressing hla-e
AU2020245045A1 (en) * 2019-03-26 2021-11-18 Promethera Therapeutics Sa Adult liver progenitor cells for treating acute-on-chronic liver failure
US20220202874A1 (en) 2019-03-26 2022-06-30 Promethera Therapeutics Sa Adult Liver Progenitor Cells for Treating Non-Alcoholic Fatty Liver Disease
TW202106874A (zh) 2019-04-30 2021-02-16 比利時商普羅米修亞生物科技股份有限公司 人類同種異體肝衍生前驅細胞的製備(一)
PL3963050T3 (pl) 2019-04-30 2024-03-18 Cellaïon SA Przygotowanie ludzkich allogenicznych komórek progenitorowych pochodzących z wątroby
EP4041261A1 (en) 2019-10-09 2022-08-17 Cellaion SA Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability
EP3881853A1 (en) 2020-03-20 2021-09-22 Promethera Therapeutics Sa Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation
CN111778268B (zh) * 2020-06-03 2022-06-21 武汉仝干医疗科技股份有限公司 增强解毒功能基因片段及改造的HepG2细胞
WO2023180122A1 (en) 2022-03-24 2023-09-28 Université Catholique de Louvain Use of human allogenic liver-derived progenitor cells for treating and/or preventing cellular senescence

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126219A1 (en) * 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
CN103989710B (zh) * 2005-12-21 2019-11-15 鲁汶大学 分离的肝脏干细胞
ES2359874T5 (es) * 2005-12-21 2014-12-12 Universite Catholique De Louvain Células madre hepáticas aisladas
EP2295537A4 (en) * 2008-05-14 2011-11-30 Public Univ Corp Yokohama City HUMAN HEPATIC STRAIN CELL, PREPARATION METHOD THEREFOR, METHOD OF INDUCING ITS DIFFERENTIATION AND METHOD OF USE
US8415149B2 (en) * 2010-05-06 2013-04-09 Gwo Xi Stem Cell Applied Technology Co., Ltd. Hepatic progenitor cells and uses thereof
WO2013110354A1 (en) * 2012-01-25 2013-08-01 Université Catholique de Louvain Compositions and methods for cell transplantation
ES2759228T3 (es) 2013-07-05 2020-05-08 Univ Catholique Louvain Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado
KR20190022939A (ko) * 2013-08-28 2019-03-06 프로메테라 바이오사이언시즈 에스.에이./엔.브이. 성체 간 전구 세포 제조 방법

Also Published As

Publication number Publication date
MX2018010508A (es) 2018-11-09
CA3013427A1 (en) 2017-09-08
BR112018067597A8 (pt) 2019-10-15
IL261383A (en) 2018-10-31
CN108779440A (zh) 2018-11-09
EA039743B1 (ru) 2022-03-05
WO2017149059A1 (en) 2017-09-08
BR112018067597A2 (pt) 2019-01-08
EP3423566A1 (en) 2019-01-09
US20190046584A1 (en) 2019-02-14
KR20180114073A (ko) 2018-10-17
JP2019506890A (ja) 2019-03-14
AU2017225825A1 (en) 2018-08-16
SG11201807041PA (en) 2018-09-27
MA45274A (fr) 2019-01-09

Similar Documents

Publication Publication Date Title
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
PH12018502429A1 (en) Antibody molecules for cancer treatment
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EP4306166A3 (en) Compounds, compositions and methods of use
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA201890278A1 (ru) Антитела к pd-l1
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MX2018007089A (es) Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
EA201792047A1 (ru) Новые соединения
EA201991214A1 (ru) Антитела против pd-1 и их композиции
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201591762A1 (ru) Человеческие антитела к grem1
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
CA3010708A1 (en) Methods of administering hepcidin
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
WO2018138032A3 (en) NKp46 BINDING AGENTS